Baseline characteristics and IEC toxicities
| Baseline characteristics and IEC toxicity . | Patients with BCMA, N = 234 . |
|---|---|
| Demographics | |
| Age, median (IQR) | 66 (59.9-72.5) |
| Male sex, n (%) | 132 (56.8) |
| Disease status | |
| MM type, n (%) | |
| IgG | 112 (47.9) |
| IgA | 51 (21.8) |
| IgM | 1 (0.4) |
| IgD | 1 (0.4) |
| Light chain | 67 (28.6) |
| Oligo/nonsecretory | 2 (0.9) |
| Prior line of therapy, median (IQR) | 6 (4-8) |
| Prior autologous SCT, n (%) | 161 (68.8) |
| BCMA CAR T-cell product, n (%) | |
| Idecabtagene vicleucel | 139 (59.4) |
| Ciltacabtagene autoleucel | 77 (32.9) |
| Investigational autologous BCMA CAR T-cell product | 18 (7.7) |
| Years from diagnosis to BCMA CAR T cells, median (range) | 6.0 (3.5-8.8) |
| Antifungal prophylaxis, n (%) | |
| Fluconazole or micafungin prophylaxis∗ | 28 (12.0) |
| IEC toxicities | |
| CRS diagnosis | 198 (84.6) |
| Grade 1 | 127 (64.1) |
| Grade 2 | 61 (30.8) |
| Grade 3 | 10 (5.1) |
| Grade 4 | 0 (0) |
| ICANS diagnosis | 36 (15.3) |
| Grade 1 | 10 (27.8) |
| Grade 2 | 15 (41.7) |
| Grade 3 | 10 (27.8) |
| Grade 4 | 1 (2.8) |
| Atypical neurotoxicity (Bell’s palsy or parkinsonism) | 9 (3.8) |
| IEC-HS | 4 (2) |
| Treatment of IEC toxicities | |
| Any corticosteroids for treatment of IEC toxicities, n (%) | 98 (41.9) |
| Cumulative prednisone equivalent ≤200 mg | 56 (23.9) |
| Cumulative prednisone equivalent >200 and ≤1000 mg | 24 (10.3) |
| Cumulative prednisone equivalent >1000 mg | 18 (7.7) |
| Nonsteroid treatment for IEC toxicities | |
| Tocilizumab, n (%) | 132 (56.4) |
| Tocilizumab median doses (range) | 1 (1-4) |
| Anakinra, n (%) | 21 (9.0) |
| Outcomes, n (%) | |
| Disease relapse within 1 year | 102 (43.6) |
| Death within 1 year | 44 (18.8) |
| Baseline characteristics and IEC toxicity . | Patients with BCMA, N = 234 . |
|---|---|
| Demographics | |
| Age, median (IQR) | 66 (59.9-72.5) |
| Male sex, n (%) | 132 (56.8) |
| Disease status | |
| MM type, n (%) | |
| IgG | 112 (47.9) |
| IgA | 51 (21.8) |
| IgM | 1 (0.4) |
| IgD | 1 (0.4) |
| Light chain | 67 (28.6) |
| Oligo/nonsecretory | 2 (0.9) |
| Prior line of therapy, median (IQR) | 6 (4-8) |
| Prior autologous SCT, n (%) | 161 (68.8) |
| BCMA CAR T-cell product, n (%) | |
| Idecabtagene vicleucel | 139 (59.4) |
| Ciltacabtagene autoleucel | 77 (32.9) |
| Investigational autologous BCMA CAR T-cell product | 18 (7.7) |
| Years from diagnosis to BCMA CAR T cells, median (range) | 6.0 (3.5-8.8) |
| Antifungal prophylaxis, n (%) | |
| Fluconazole or micafungin prophylaxis∗ | 28 (12.0) |
| IEC toxicities | |
| CRS diagnosis | 198 (84.6) |
| Grade 1 | 127 (64.1) |
| Grade 2 | 61 (30.8) |
| Grade 3 | 10 (5.1) |
| Grade 4 | 0 (0) |
| ICANS diagnosis | 36 (15.3) |
| Grade 1 | 10 (27.8) |
| Grade 2 | 15 (41.7) |
| Grade 3 | 10 (27.8) |
| Grade 4 | 1 (2.8) |
| Atypical neurotoxicity (Bell’s palsy or parkinsonism) | 9 (3.8) |
| IEC-HS | 4 (2) |
| Treatment of IEC toxicities | |
| Any corticosteroids for treatment of IEC toxicities, n (%) | 98 (41.9) |
| Cumulative prednisone equivalent ≤200 mg | 56 (23.9) |
| Cumulative prednisone equivalent >200 and ≤1000 mg | 24 (10.3) |
| Cumulative prednisone equivalent >1000 mg | 18 (7.7) |
| Nonsteroid treatment for IEC toxicities | |
| Tocilizumab, n (%) | 132 (56.4) |
| Tocilizumab median doses (range) | 1 (1-4) |
| Anakinra, n (%) | 21 (9.0) |
| Outcomes, n (%) | |
| Disease relapse within 1 year | 102 (43.6) |
| Death within 1 year | 44 (18.8) |
MM, multiple myeloma; IgG, immunoglobulin G; IQR, interquartile range; SCT, stem cell transplant.
Patients may receive micafungin per febrile neutropenia protocol.